Changes to the Datwyler Board of Directors
Ad hoc announcement pursuant to Art. 53 LR SIX Swiss Exchange | January 17, 2022
Nomination of Judith van Walsum and resignation of Hanno Ulmer.
The Dätwyler Holding Inc. Board of Directors has decided to nominate Judith van Walsum as new member of the Board and as public shareholders‘ representative at the Annual General Meeting on 16 March 2022. Hanno Ulmer is not standing for reelection due to personal reasons. Jürg Fedier, previously public share-holders‘ representative, will replace Hanno Ulmer as representative of Pema Holding AG.
Since 2018, Judith van Walsum has been Chief Financial Officer (CFO) and Head of IT at Roche Diabetes Care, a globally operating business divison of Roche Group with some 4’500 employees and over CHF 1.5 billion in revenue. As member of the Diabetes-Care leadership team, she is co-accountable for strategy development and implementation, as well as the advancement of the offer toward an integrated, personalized diabetes management.
From 2004 to 2018, the 57-year-old Dutchwoman has held diverse global managerial functions for Roche Group, among which Head of HR Operations and Head of Finance and Inter-company Supply Chain for Roche Diagnostics. From 1999 to 2004, she was Senior Manager in Financial Strategy, Process and Transformation for KPMG in Frankfurt. Judith van Walsum has undergone studies at several universities and has a Ph.D in international political economy at the London School of Economics.
With Judith van Walsum we have secured a strong personality for the Datwyler Board of Directors. Beside her broad managerial and strategic experience, she possesses deep knowledge of the global healthcare markets. She can greatly contribute to the further development of our healthcare growth strategy. I would like to thank Hanno Ulmer for his valuable collaboration in the Datwyler board of directors during the past seven years and wish him the best of luck in his future activities.
Chairman
Enquiries
Guido Unternährer
VP Financial Communication & Investor Relations
Further information
